Patents by Inventor Robert A. Lipper
Robert A. Lipper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170079999Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: December 6, 2016Publication date: March 23, 2017Inventors: Terrence C. DAHL, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLIYAI, Taiyin YANG
-
Patent number: 9545414Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: March 6, 2015Date of Patent: January 17, 2017Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCInventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20150174147Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: March 6, 2015Publication date: June 25, 2015Inventors: Terrence C. Dahl, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLlYAI, Taiyin YANG
-
Patent number: 9018192Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: October 10, 2013Date of Patent: April 28, 2015Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20140037724Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCInventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Patent number: 8598185Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: June 13, 2006Date of Patent: December 3, 2013Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20070099902Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: June 13, 2006Publication date: May 3, 2007Inventors: Terrence Dahl, Munir Hussain, Robert Lipper, Robert Jerzewski, Mark Menning, Reza Oliyai, Taiyin Yang
-
Patent number: 5244891Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.Type: GrantFiled: May 22, 1992Date of Patent: September 14, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
-
Patent number: 5034397Abstract: This invention relates to novel compositions of the antitumor agent [4'-9-(acridinylamino) methanesulfon-m-anisidide], (m-AMSA). Acid salts of m-AMSA are dissolved in 1-methyl-2-pyrrolidinone to provide highly stable solutions. The solutions may be diluted with Sterile Water for Injection, U.S.P. to provide stable, non-precipitating solutions for intravenous use.Type: GrantFiled: December 12, 1985Date of Patent: July 23, 1991Assignee: Bristol-Myers Squibb Co.Inventors: Murray A. Kaplan, Robert A. Lipper
-
Patent number: 4994451Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.Type: GrantFiled: December 11, 1989Date of Patent: February 19, 1991Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
-
Patent number: 4910301Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.Type: GrantFiled: January 19, 1988Date of Patent: March 20, 1990Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
-
Patent number: 4754030Abstract: The crystalline triethylamine salt of cefbuperazone is stable in the dry state and soluble in water and in aqueous injection vehicles.Type: GrantFiled: February 1, 1985Date of Patent: June 28, 1988Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Robert A. Lipper
-
Patent number: 4680389Abstract: Crystalline adducts of 7-[(Z)-2-methoxyimino-2-(2-aminothiazol-4-yl)acetamido-3-[(1-methyl-1-pyrr olidinium)methyl]-3-cephem-4-carboxylate selected from the group consisting of the di(1-methyl-2-pyrrolidinone) adduct and the di(N-formyl pyrrolidine) adduct and salt complexes thereof have been found to be stable at even high temperatures. The crystalline adducts are prepared by forming an admixture of adducting agents, zwitterions and seed adduct crystals and inducing crystallization followed by isolating the crystals. A process for preparing adduct salt complexes is also disclosed. Crystalline zwitterion can be formed by slurrying the adducts in a solvent which removes the adducting agents.Type: GrantFiled: January 10, 1986Date of Patent: July 14, 1987Assignee: Bristol-Myers CompanyInventors: Murray A. Kaplan, Joseph B. Bogardus, Robert A. Lipper